The global market for ADME-Toxicology Testing was valued at US$10.0 Billion in 2024 and is projected to reach US$18.8 Billion by 2030, growing at a CAGR of 11.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The demand for ADME-Toxicology testing has surged with the expansion of the pharmaceutical industry and the introduction of more complex biologic drugs which require intricate safety assessments. Modern testing methods now often employ sophisticated technologies such as high-throughput screening and molecular modeling to predict ADME-Tox profiles efficiently and accurately. Additionally, the integration of in vitro and in silico models has enhanced the predictive capabilities of these tests, reducing the reliance on animal testing and aligning with the global push towards more ethical research practices. These advancements not only expedite the drug development process but also improve its cost-effectiveness, enabling researchers to screen out potential failures earlier in the development cycle. The increasing complexity of new therapeutic agents, including targeted therapies and personalized medicine, further necessitates the detailed and precise analysis provided by advanced ADME-Tox studies.
The growth in the ADME-Toxicology testing market is driven by several factors. Technological advancements that offer more rapid, accurate, and cost-effective testing methods are a primary driver. As pharmaceutical companies continue to seek ways to reduce the time and cost associated with drug development, these advanced technologies become increasingly attractive. Additionally, regulatory requirements have become more stringent worldwide, demanding more comprehensive toxicity and efficacy data before a drug can be approved. This regulatory landscape ensures continual demand for ADME-Tox testing services. Moreover, the growing focus on personalized medicine and the development of drugs with narrower therapeutic indices call for more detailed and customized toxicity testing, further propelling the market. Finally, the ethical push towards reducing animal testing in drug development encourages the adoption of alternative in vitro and in silico methods, aligning market expansion with broader ethical standards. These factors collectively ensure sustained growth in the ADME-Toxicology testing market, highlighting its critical role in advancing safe and effective pharmaceuticals.
Global ADME-Toxicology Testing Market - Key Trends and Drivers Summarized
ADME-Toxicology Testing is a critical process in pharmacology, referring to the assessment of Absorption, Distribution, Metabolism, and Excretion (ADME) properties of potential pharmaceutical compounds alongside their toxicological profiles. This type of testing is fundamental in drug development, providing essential data that predicts how substances behave in the body, which can impact drug safety and efficacy. The toxicological tests evaluate potential adverse effects caused by drug candidates, helping to identify any toxic risk associated with drug intake. ADME-Toxicology testing is not only a regulatory requirement but also a crucial step to ensure that only safe and efficacious drugs reach clinical trials and eventually the market, thereby safeguarding public health.The demand for ADME-Toxicology testing has surged with the expansion of the pharmaceutical industry and the introduction of more complex biologic drugs which require intricate safety assessments. Modern testing methods now often employ sophisticated technologies such as high-throughput screening and molecular modeling to predict ADME-Tox profiles efficiently and accurately. Additionally, the integration of in vitro and in silico models has enhanced the predictive capabilities of these tests, reducing the reliance on animal testing and aligning with the global push towards more ethical research practices. These advancements not only expedite the drug development process but also improve its cost-effectiveness, enabling researchers to screen out potential failures earlier in the development cycle. The increasing complexity of new therapeutic agents, including targeted therapies and personalized medicine, further necessitates the detailed and precise analysis provided by advanced ADME-Tox studies.
The growth in the ADME-Toxicology testing market is driven by several factors. Technological advancements that offer more rapid, accurate, and cost-effective testing methods are a primary driver. As pharmaceutical companies continue to seek ways to reduce the time and cost associated with drug development, these advanced technologies become increasingly attractive. Additionally, regulatory requirements have become more stringent worldwide, demanding more comprehensive toxicity and efficacy data before a drug can be approved. This regulatory landscape ensures continual demand for ADME-Tox testing services. Moreover, the growing focus on personalized medicine and the development of drugs with narrower therapeutic indices call for more detailed and customized toxicity testing, further propelling the market. Finally, the ethical push towards reducing animal testing in drug development encourages the adoption of alternative in vitro and in silico methods, aligning market expansion with broader ethical standards. These factors collectively ensure sustained growth in the ADME-Toxicology testing market, highlighting its critical role in advancing safe and effective pharmaceuticals.
Scope of the Study
The report analyzes the ADME-Toxicology Testing market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments:
Technology (Cell Culture, High Throughput Screening, Molecular Imaging, OMICS, Other Technologies); Method (Cellular Assay, Biochemical Assay, Ex-Vivo, In Silica); Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, Other Applications).Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Cell Culture Technology segment, which is expected to reach US$9.6 Billion by 2030 with a CAGR of a 13.2%. The High Throughput Screening Technology segment is also set to grow at 8.0% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $4.5 Billion in 2024, and China, forecasted to grow at an impressive 14.4% CAGR to reach $1.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Corning, Inc., BD Biosciences, Charles River Laboratories International, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global ADME-Toxicology Testing Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global ADME-Toxicology Testing Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global ADME-Toxicology Testing Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 79 major companies featured in this ADME-Toxicology Testing market report include:
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Corning, Inc.
- BD Biosciences
- Charles River Laboratories International, Inc.
- AB Sciex LLC
- Dassault Systemes SE (3DS)
- Cyprotex Limited
- BioReliance Corporation
- Crown Bioscience, Inc.
- Envigo, Inc.
- ADMEcell, Inc.
- Endonovo Therapeutics, Inc.
- CN Bio Innovations Ltd.
- Emulate, Inc.
Table of Contents
I. METHODOLOGYMII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPEIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Corning, Inc.
- BD Biosciences
- Charles River Laboratories International, Inc.
- AB Sciex LLC
- Dassault Systemes SE (3DS)
- Cyprotex Limited
- BioReliance Corporation
- Crown Bioscience, Inc.
- Envigo, Inc.
- ADMEcell, Inc.
- Endonovo Therapeutics, Inc.
- CN Bio Innovations Ltd.
- Emulate, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 472 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 10 Billion |
| Forecasted Market Value ( USD | $ 18.8 Billion |
| Compound Annual Growth Rate | 11.2% |
| Regions Covered | Global |
